Atlantic Pharmaceuticals, Inc., is a privately held specialty pharmaceutical company dedicated to the discovery and development of innovative, late stage therapies for substance abuse and pain related conditions.
Our current product development candidates are targeted toward abuse deterrent orally administered opioid dosage forms which have the potential to greatly diminish non-oral abuse and misuse. These opportunities utilize molecules shown to be safe and effective with formulations that are protected by intellectual property and a clear and shotened regulatory pathway. We believe that our approach will lead to improved patient care, reduced healthcare costs, a reduced development risk and a rapid time to market.
The company is using its proprietary SMART/Script™ platform to formulate ATLP-02, which is an tamper resistant, immediate release, orally delivered oxycodone dosage form.